Using a mouse parthenogenetic system, effects of ICRF-193, a noncleavable complex-forming topoisomerase II inhibitor, on female meiosis II chromosomes and pronuclear chromosomes were studied. Eggs were exposed to the inhibitor (10 µM) at various times after parthenogenetic stimulation, and chromosomes of them were analyzed at the first cleavage metaphase. When eggs were exposed to the inhibitor during the period from metaphase II to anaphase II, a significant increase in incidences of structural chromosome aberrations (51.1% vs. 1.3% in the control) and aneuploidy (30.3% vs. 0.7% in the control) was found. Structural chromosome aberrations were observed in 10-20% of eggs following treatments during telophase II, but there was no increased incidence of aneuploidy in treatments during this meiotic stage. When pronuclear eggs at S phase were targeted by the inhibitor, no significant increase in chromosome aberrations was found. 
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Introduction
Topoisomerase II is a ubiquitous nuclear enzyme that is involved in chromosome condensation and chromosome segregation during mitosis and meiosis [1, 2] . Therefore, topoisomerase II interactive agents have potential clastogenic and aneugenic actions on meiotic cells. Etoposide, a specific topoisomerase II inhibitor, caused both structural chromosome aberrations and aneuploidy in primary oocytes of the mouse [3, 4] and the Chinese hamster [5] . Similar chromosomal effects of the inhibitor were found in mouse primary spermatocytes [6, 7] . Another topoisomerase II inhibitor, merbarone, caused aneuploidy in mouse primary spermatocytes without formation of structural chromosome aberrations [8] . Studies also revealed that the sensitivity of these meiotic cells to topoisomerase II inhibitors was stage-dependent. Oocytes from late dictyate to diakinesis [5] , and spermatocytes from pachytene to diakinesis [6] [7] [8] were highly sensitive. 
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On the other hand, it is premature to conclude that inhibition of topoisomerase II activity during meiosis II can induce chromosome aberrations. Kallio and Lähdetie [6] found a significant increase of micronuclei in mouse spermatids following treatment with etoposide during meiosis II. However, meiosis II chromosomes were much less sensitive to the inhibitor than meiosis I chromosomes. Subsequently, the investigators failed to find a significant increase of spermatid micronuclei after treatment with merbarone [8] . Mailhes et al. [4] found in the mouse that incidence of chromosome aberrations was higher in 1-cell zygotes than in MII oocytes when etoposide was administered during preovulatory stage.
The investigators have suggested that the inhibitor may cause chromosome aberrations during female meiosis II. However, no attempt has been made to obtain direct evidence that topoisomerase II inhibitors can induce chromosome aberrations in mammalian secondary oocytes.
In this study, we examined clastogenic and aneugenic effects of a noncleavable complex-forming topoisomerase II inhibitor, ICRF-193, on mouse oocytes during meiosis II in order to evaluate the heritable risk of topoisomerase II inhibitors and to understand the mechanism of chromosome aberration formation. Our interest further extended to the chromosomal sensitivity of pronuclear eggs. For these purposes, we utilized a mouse parthenogenetic system since mouse oocytes are easily activated by physical and chemical stimulation, and parthenogenetically activated eggs normally complete the second meiotic division and develop beyond the first cleavage mitosis [9] . Approximately 2 h before use, the inhibitor was diluted with an appropriate medium to a final concentration of 10 µM. The final concentration of DMSO was 0.1%.
Media
CZB medium supplemented with 5.56 mM D-glucose [10] was used for culturing parthenogenetic mouse eggs. Oocytes were collected in Hepes-buffered CZB containing 20 mM Hepes-HCl, 5 mM NaHCO 3 , and 0.1 mg/ml polyvinyl alcohol in lieu of bovine serum 6 albumin (BSA). The pH was adjusted to approximately 7.4 using 1 N HCl. The CZB was used under 5% CO 2 in air, and Hepes-buffered CZB was used under 100% air. B6D2F1 hybrid female mice 7-12 weeks of age were used in this study. They were maintained under a 14 h-light/10 h-dark photoperiod at a temperature of 23±2 ˚C and humidity of 40-60%. Food and water were given ad libitum.
Animals

Parthenogenetic activation of oocytes
Females were induced to superovulate by an intraperitoneal injection of 8 iu pregnant mare's serum gonadotropin (PMSG) followed 48 h later with an injection of 8 iu human chorionic gonadotropin (hCG). Oocytes at metaphase II were collected from oviducts between 15 h and 16 h after hCG injection and were treated with 0.1% hyaluronidase for 3-5 min in Hepes-buffered CZB to remove cumulus cells. Strontium chloride (SrCl 2 ) was used to induce parthenogenetic activation [11] because it does not affect chromosome segregation in mouse oocytes during meiosis II [12] . Cumulus-free oocytes were incubated in 5 mM SrCl 2 in Ca-free CZB for 2 h. The activated eggs were then transferred to CZB for further cultivation.
Progression of meiosis II and timing of DNA synthesis in recently activated eggs
Prior to treatment with ICRF-193, the time-course progression of meiosis II and the timing of DNA synthesis in recently activated eggs were determined. As mentioned above, oocytes were collected from 6 females and parthenogenetically activated. At 0.5 h, 1.0 h, 2.0 h, 4.0 h and 6.0 h after parthenogenetic stimulation, 30-40 eggs were taken from the culture and treated with 0.5% protease (Kaken Pharmaceuticals, Tokyo, Japan) for 10 min at room temperature (25-26 ˚C) to remove the zona pellucida. They were fixed and placed on microscopic glass slides by gradual-fixation/air-drying method [13] . The slides were stained with 2% Giemsa (Merck, Darmstadt, Germany) in phosphate buffered solution (pH 6.8). To determine S phase, eggs were labelled with 10 µM bromodeoxyuridine (BrdU) for the periods between 4 h and 6 h, and between 6 h and 8 h after parthenogenetic stimulation. As described by Aoki and Schultz [14] , eggs were washed with PBS containing 0.3% BSA (PBS/BSA), and fully fixed with 3.7% formaldehyde. After washing with PBS/BSA, the DNA was denatured by incubating the eggs in 2N HCl for 1 h at 37 ˚C. The eggs were then neutralized with borate buffer (pH 8.6) for 15 min. To detect incorporation of BrdU, the eggs were incubated with mouse anti-BrdU monoclonal antibody (Roche, Mannheim, Germany) for 45 min at 37 ˚C. The eggs were then incubated with fluorescein-conjugated anti-mouse IgG (Roche) for 45 min at 37 ˚C. They were then mounted on poly -L-lysine coated-glass slides, and covered with Vectashield mounting medium (Vector, CA) for fluorescent microscopy. 
Treatment with ICRF-193
To investigate the effects of ICRF-193 on eggs at various stages from metaphase II through S phase, eggs were treated by incubating them in medium supplemented with 10 µM ICRF-193 at predetermined periods after parthenogenetic stimulation. Time and duration of the treatment were determined as mentioned earlier (see Table 1 ). Eggs exposed to 0.1% DMSO alone served as the control for the solvent. 
Chromosome preparation and analysis
Eight hours after parthenogenetic stimulation, eggs were transferred to CZB containing 0.008 µg/ml vinblastine and cultured until they reached the first cleavage metaphase. Between 18 h and 20 h post-stimulation, metaphase eggs were treated with 0.5% protease for 5-6 min at room temperature to loosen the zona pellucida. They were then exposed to a hypotonic solution (1:1 mixture of 1% sodium citrate and 30% fetal bovine serum) for 10 min at room temperature. Chromosome preparations were made by the gradual-fixation/air-drying method [13] . The chromosome spreads were stained with 2% Giemsa for 8 min for conventional chromosome analysis. Subsequently, chromosomes were C-banded to identify the centromeres according to Sumner [15] with some modifications. In brief, the slides were heated at 50 ˚C for 2-3 h to harden the eggs. They were then treated with 0.2N HCl for 30 min at room temperature, 5% Ba(OH) 
Statistical analysis
Fisher's exact probability test was used to compare results between control and experimental groups. Differences at p < 0.05 were considered significant. 
Results
Meiosis II and DNA synthesis in recently activated eggs
Chromosome analysis
In all experimental groups, more than 97% of oocytes successfully underwent parthenogenetic activation, and almost all (93-99%) of the activated eggs were able to proceed to the first mitotic metaphase. The findings indicate that ICRF-193 at a concentration of 10 µM does not prevent activation, second polar body formation (cytokinesis), chromosome decondensation, pronuclear formation, DNA synthesis and chromosome condensation in mouse eggs.
Eggs exposed to DMSO alone, whether during incubation for parthenogenetic activation or after, showed similarly low incidences of chromosome aberrations. Hence, data from both groups were combined as the non-treated control (Table 2) While etoposide frequently induces centromeric breaks in mouse primary oocytes [3] and mouse primary spermatocytes [6, 7] , these were not predominantly shown in this study using To observe chromosomal behavior during anaphase II/telophase II in the presence of ICRF-193, cytological preparations of oocytes during these stages (approximately 0.5 h post-stimulation) were made by the gradual-fixation/air-drying method [13] . In this 
Discussion
The present results demonstrated that inhibition of topoisomerase II activity by ICRF-193 during meiosis II is responsible for induction of structural chromosome aberrations and aneuploidy in mouse eggs. In addition, it was found that sensitivity to the inhibitor was stage-dependent, as the cell stage during ICRF-193 treatment clearly determined the incidence of aberrant eggs (Table 2 and Figure 3 ).
Mechanisms behind the chromosome aberrations caused by topoisomerase II inhibitors have been proposed in studies with somatic cells. It is generally accepted that the induction of numerical aberrations is due to incomplete separation of sister chromatids at the onset of anaphase by inhibition of topoisomerase II decatenation activity [16] [17] [18] [19] [20] [21] [22] [23] [24] . In our anaphase II/telophase II assay of treated eggs, lagging chromatids were frequently observed at the spindle equator (Figure 2b ). Since ICRF-193 does not interact with spindle fibers [21] , it seems likely that lagging chromatids are generated when the inhibitor disrupts the separation of sister centromeres at anaphase II, thus resulting to aneuploidy.
There is considerable mystery in connection with mechanism(s) behind the formation of structural chromosome aberrations by ICRF-193. It is believed that the clastogenic property of topoisomerase II inhibitors depends on whether they are capable of forming cleavable complexes, since stabilized cleavable complexes cause structural chromosome aberrations. For example, complex-forming agents including amsacrine, doxorubicin, daunorubicin, etoposide, mitoxantrone and teniposide have been demonstrated to cause structural chromosome aberrations in various types of somatic cells in Sindependent manner [24] [25] [26] . Undoubtedly, etoposide can cause structural chromosome aberrations in mammalian meiotic cells [3] [4] [5] [6] [7] . In contrast, a noncomplex-forming inhibitor, such as merbarone, does not generate structural chromosome aberrations in mouse spermatocytes [8] and DNA breaks in mouse leukemia cells [27] . Like merbarone, ICRF-193 can inhibit topoisomerase II activity without forming a cleavable complex [28, 29] . It has no ability to generate DNA strand breaks [19] . However, a significant increase in structural chromosome aberrations has been found in Chinese hamster V79 cells exposed to ICRF-193 from late S phase to G were found during anaphase following treatment with etoposide [16, 24] and ICRF-193 [19] .
In the present results, however, no recognizable chromosomal bridges appeared in the anaphase II/telophase II chromosomes following ICRF-193 treatment. Therefore, it is unlikely that ICRF-193 causes chromosome breaks in mouse secondary oocytes through chromosome stickiness.
We found that treatment with ICRF-193 from metaphase II through anaphase II was most effective in inducing structural chromosome aberrations, and many of the induced aberrations were of chromosome-type (Table 2 ). This suggests that ICRF-193-induced some harmful changes in topoisomerase II can be converted into double-strand breaks in chromosome DNA. It is well known that topoisomerase II plays a role as scaffold protein of metaphase chromosomes, and chromatin fiber is associated with the chromosome scaffold 
